PACIRA BIOSCIENCES, INC. Severance Costs
PACIRA BIOSCIENCES, INC. (PCRX) reported Severance Costs of $3.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. severance costs for the quarter ending 2025-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. severance costs for the quarter ending 2025-09-30 was $3.70M.
- PACIRA BIOSCIENCES, INC. severance costs for the quarter ending 2020-03-31 was $0.00.
- PACIRA BIOSCIENCES, INC. severance costs for the quarter ending 2019-12-31 was -$51.00K.
- PACIRA BIOSCIENCES, INC. severance costs for fiscal 2025 was $3.70M.
- PACIRA BIOSCIENCES, INC. severance costs for fiscal 2019 was $429.00K.
- PACIRA BIOSCIENCES, INC. severance costs for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PACIRA BIOSCIENCES, INC. severance costs for fiscal 2017 was $303.00K.
| Period end | Severance Costs 3 month | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.70M derived: sum of 2 quarters · filed 2026-02-26 | $3.70M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $3.70M 10-Q · filed 2025-11-06 | $3.70M 10-Q · filed 2025-11-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | -$51.00K derived: sum of 2 quarters · filed 2020-05-07 | $39.00K derived: sum of 3 quarters · filed 2020-05-07 | |
| 2019-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $39.00K derived: sum of 2 quarters · filed 2020-02-21 | $429.00K 10-K · filed 2020-02-21 | |
| 2019-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $480.00K 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $390.00K 10-Q · filed 2019-08-08 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-02-21 | |||
| 2017-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$62.00K derived: sum of 2 quarters · filed 2020-02-21 | $303.00K 10-K · filed 2020-02-21 | |
| 2017-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $309.00K 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | $365.00K 10-Q · filed 2017-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |